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Abstract
Background: Regenerative strategies in the treatment of acute stroke may have great potential. Hematopoietic growth
factors mobilize hematopoietic stem cells and may convey neuroprotective effects. We examined the safety, potential
functional and structural changes, and CD34+ cell–mobilization characteristics of G-CSF treatment in patients with acute
ischemic stroke.
Methods and Results: Three cohorts of patients (8, 6, and 6 patients per cohort) were treated subcutaneously with 2.5, 5, or
10 mg/kg body weight rhG-CSF for 5 consecutive days within 12 hrs of onset of acute stroke. Standard treatment included
IV thrombolysis. Safety monitoring consisted of obtaining standardized clinical assessment scores, monitoring of CD34+
stem cells, blood chemistry, serial neuroradiology, and neuropsychology. Voxel-guided morphometry (VGM) enabled an
assessment of changes in the patients’ structural parenchyma. 20 patients (mean age 55 yrs) were enrolled in this study, 5 of
whom received routine thrombolytic therapy with r-tPA. G-CSF treatment was discontinued in 4 patients because of
unrelated adverse events. Mobilization of CD34+ cells was observed with no concomitant changes in blood chemistry,
except for an increase in the leukocyte count up to 75,500/ml. Neuroradiological and neuropsychological follow-up studies
did not disclose any specific G-CSF toxicity. VGM findings indicated substantial atrophy of related hemispheres, a substantial
increase in the CSF space, and a localized increase in parenchyma within the ischemic area in 2 patients.
Conclusions: We demonstrate a good safety profile for daily administration of G-CSF when begun within 12 hours after
onset of ischemic stroke and, in part in combination with routine IV thrombolysis. Additional analyses using VGM and a
battery of neuropsychological tests indicated a positive functional and potentially structural effect of G-CSF treatment in
some of our patients.
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Introduction
Cerebrovascular disorders, specifically ischemic stroke, remain
the third most common cause of death and a leading cause of
disability [1], their significance steadily increasing due to
demographic changes in western industrial societies. The intro-
duction of intravenous (IV) thrombolysis with recombinant tissue
plasminogen activator (rtPA) more than a decade ago was a
milestone in stroke therapy; however, only a minority of patients
benefit from this treatment due to the narrow time window of its
effectiveness [2,3,4,5]. Although a number of treatment targets
within the cascade of neuronal death have been identified,
neuroprotective strategies so far have proved to be a constant
source of disappointment [6,7].
Despite these setbacks, neuroregeneration, neuroplasticity and
neuronal repair still may have the potential to improve functional
and structural outcome once normal cerebral blood flow has been
reestablished, if the prior ischemic environment favors repair.
Similar to other organs, endogenous stem cells and progenitor cells
are already present in the brai, mainly in the hippocampus and the
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subventricular zone [8,9]. In addition, hematopoietic stem cells
appear to be mobilized by the cerebral ischemic event and have
the potential to home in on damaged brain parenchyma [10].
Since neural stem cells and precursor cells are the most hypoxia-
resistant cells [11], they may survive the critical hypoxic phase of
ischemia. These pluripotent cells have the capacity to differentiate
into neurons, astrocytes, oligodendrocytes, and endothelial cells.
Reports on different experimental stroke models indicate that stem
cells can survive, integrate, and even operate as neurons
[12,13,14].
Granulocyte colony-stimulating factor (G-CSF) is a 19.6-kDa
glycoprotein that regulates the generation, proliferation, survival,
and maturation of neutrophilic granulocytes [15]. G-CSF acts via
the G-CSF receptor (G-CSFR), a single transmembrane protein
belonging to the hematopoietin receptor superfamily, and is
expressed on a variety of hematopoietic and neuronal cell types
[16]. Its expression in the brain has been described in the cortex
[16,17], hippocampus, and subventricular zone among others
(cerebellum and brainstem nuclei) [17,18]. G-CSF has been used
extensively in the last decades to mobilize CD34+ hematopoietic
stem cells in neutropenic patients and for reconstitution of bone
marrow [19,20]. It has been shown to be safe with only a few well-
described side effects.
Over the last few years evidence has emerged that G-CSF has a
therapeutic potential in stroke. It has been shown to exhibit
neuroprotective and regenerative activity in experimental stroke
models [16,21,22,23,24,25]. Initial clinical phase II studies on the
use of systemically administered G-CSF in patients have also
shown promising results [26,27]. However, the timing, route of
application, dosing, and length of G-CSF treatment have not yet
been thoroughly investigated.
We report the results of an open-label acute ischemic-stroke
phase I/II trial centered on the use of 5 daily subcutaneous
injections of human recombinant G-CSF to mobilize CD34+ cells
in a dose-escalation trial in acute stroke patients. Secondary
outcome parameters included neuropsychological testing and
voxel-guided morphometry (VGM). As an extension to previous
studies, IV thrombolysis in acute stroke was allowed, adding to the
safety profile of this approach.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Treatment
The study was approved by the local institutional review board
in accordance with the guidelines of Helsinki, and written
informed consent was obtained from each patient. All amend-
ments to the original protocol were approved by the local ethics
committee and are attached as Amendment S1. Changes included
the method of VGM for analysis of the acquired MRI data sets,
additional MRI follow-up in selected patients after 5 years, and a
higher leucocyte count at which a dose reduction in GCF-F would
be initiated (described in this paper).
The trial is registered at the German Clinical Trial Register
with the number DRKS 00000723.
GCS-F (NeupogenH, Amgen, Munich) was administered as a
subcutaneous injection over a 5-day-period in a dose-escalation
design. The initial daily dose of G-CSF was 2.5 mg/kg(bodyweight,
bw) in the first 8 patients; this dose was escalated to 5 mg/kg(bw) in
6 patients and again to a final dose of 10 mg/kg(bw) in the last 6
patients. The study drug was administered within 12 hrs after
stroke onset. Subsequent doses were given at 24-hr intervals. In
agreement with the predefined safety parameters of the initial
study protocol, the G-CSF dose was tapered from 2.5 mg to
1.25 mg (a 50% dose reduction) in cases in which leukocyte counts
exceeded 20,000/ml. After the first 8 patients displayed no adverse
events due to leukocytosis, the protocol was amended to state that
a dose reduction should occur at a leukocyte threshold .50,000/
ml.
Inclusion and exclusion criteria
Patients suffering from acute middle cerebral artery ischemic
stroke and moderate neurological deficits (National Institute of
Health Stroke Scale [NIHSS] Score 4 to 22) were the target
population in this study. Patients were enrolled in the study within
12 hrs after onset of symptoms (Table 1).
Standard stroke care/thrombolytic therapy
Full standard stroke care was given to every patient.
Concomitant treatments included fluid supplement, antiplatelet
or anticoagulant medications, antibiotics, antihypertension drugs,
fever control, and insulin when medically indicated. Thrombolytic
therapy with standard IV rtPA (0.9 mg/kg bw) was initiated
within 3 hours of stroke onset, in accordance with international
guidelines.
Safety - clinical parameters
The degree of each patient’s neurological deficit(s) was assessed
using the National Institute of Health Stroke Scale (NIHSS), the
Barthel Index (BI), and the modified Rankin Scale (mRS) at study
inclusion. The BI and mRS assessments were repeated at 24 hours
and on Days 7, 28 and 90. In addition, NIHSS scores were
recorded within 24 hours and daily up to Day 7. Significant
deterioration leading to adverse events was defined as decreases
from baseline of 4 points in the NIHSS score, 10 points in the BI,
and 2 points in the mRS.
Attention was directed to thrombotic complications such as
pulmonary embolism, deep venous thrombosis, and cerebral
venous thrombosis. General vital parameters (heart rate, blood
pressure, and temperature) were routinely monitored and included
in the primary safety analysis.
Clinical laboratory parameters
Clinical chemistry monitoring, including tests of blood count, C-
reactive protein (CRP), electrolytes, liver enzymes, renal function,
lipids, and coagulation parameters, was performed on Days 1
through 7 and on Days 14, 28, and 90. Significant toxicity was
assumed when liver enzymes increased 3-fold over standard
values, renal clearance decreased to 50% of baseline, and a
decrease in the number of platelets and/or red blood cells reached
below 50% of baseline. Quantitative determination of circulating
hematopoietic stem- and progenitor cells (CD 34+) was conducted
on Days 1, 4, 7, 28, and 90 according to the modified ISHAGE
guidelines [28] by using a single-platform no-wash technique: two
technical modifications were used (PharMingen, San Diego, USA;
Becton Dickinson, Heidelberg, resp. Beckman-Coulter, Krefeld,
Germany).
Neuroradiological investigations
Brain hemorrhage was disclosed using standard cerebral
computed tomography (cCT) prior to study inclusion. Magnetic
resonance imaging (MRI) was performed within 48 hrs after
admission and on Days 7 and 90 (2 patients underwent additional
late follow-up investigations). The following MR sequences were
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used: T1- and T2-weighted, fluid-attenuated inversion recovery
(FLAIR), diffusion-weighted MRI (DWI), apparent diffusion
coefficient (ADC), high-resolution sagittal MPRAGE-T1, and
time-of-flight magnetic resonance angiography (TOF-MRA).
Adverse events were suspected if any of the following were found:
significant and/or unexpected enlargement of the ischemic area,
recurrent vascular occlusion, prolonged edema, atypical reperfu-
sion, or any type of CNS hemorrhage except minor hemorrhagic
transformation.
Neuropsychological assessment
All evaluable patients underwent a battery of neuropsycholog-
ical tests on Day 7; a subpopulation of eight patients underwent
additional tests on Day 90. The tests were performed to assess
verbal and nonverbal intelligence, long-term memory and working
memory, and attention and word fluency. Details of the test
battery can be found in another publication [29].
Voxel-guided morphometry (VGM)
The volumetric method used in this study was voxel-guided
morphometry (VGM), the details of which have been described
elsewhere [30]. In principle, a combination of linear and nonlinear
transformation processes is used to register consecutive 3D data
sets from 2 or more time points in the same individual. This allows
the clinician to follow individual structural changes within the
brain volume on a voxel-by-voxel basis. VGM from high-
resolution MPRage datasets consists of four steps. The first step
is a coarse linear alignment by the extended principle axes theory
(ePAT) generalized to affine movements; the second, a cross-
correlation–based technique involving a matrix norm for fine
linear alignment; and the third, an applied high-dimensional
multiresolution full-multigrid method used to determine nonlinear
deformations, thereby achieving a complete exploitation of
information and effective processing. This method is used to
measure a gray value–guided movement of each voxel from source
to target. The resulting high-dimensional deformation field is
further processed using a fourth step, the determination of volume
alterations for each voxel. In a subpopulation of evaluable patients
(N= 8, 3 female, 5 male) VGM was performed (table S1). The
main endpoint criteria here were defined as any change in gray
matter, white matter, or cerebral spinal fluid (CSF) space,
expressed as a percentage change in the individual patient. In 2
patients long-term follow-up was performed after 5 years (Patients
12 and 13) because volume increases in the infarct area were
observed after 3 months.
Statistical methods
All patients who received the starting dose of G-CSF were
included in the analysis and regarded as the intention-to-treat
population. For the final data analysis, however, only patients
whose treatment corresponded to the protocol were included in
our evaluation. In this open-label, single-arm dose-escalation
safety trial we chose a descriptive analysis: data are presented as
medians and all analyses were performed using SPSS software
(version 16.0; 2007 SPSS Inc.).
Neuropsychological raw data were transformed into z-scores to
transform data into normative data (related to confounders); the
definition of cut-offs for significant impairment is described
elsewhere[31]. Since only eight patients completed both neuro-
psychological assessments, Wilcoxon nonparametric tests for
comparisons of the transformed scores were computed.
Results
Patients
Twenty consecutive patients (ages 32–65 yrs, mean 55 yrs; 13
male, 7 female) were enrolled. Five patients received standard
rtPA treatment prior to study inclusion. Two patients were lost to
follow-up after Day 28 because they withdrew their consent to
participate in the study. The baseline vascular risk profiles of the
three dose groups are presented in Table 2. All 20 patients
presented with signs and symptoms of middle cerebral artery
(MCA) infarction. MRI at 48 hrs confirmed cerebral ischemia
within the MCA territory in 17 patients, within the anterior
Table 1. Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
moderate acute stroke within MCA (middle cerebral artery) territory,
specified as M2-occlusion dominant and non-dominant hemispheres
patient must comprehend the study protocol
inclusion in study protocol within 12 hours after stroke onset
age $18 years to #65 years
NIHSS Score 4–22
adequate liver function: GOT, GPT, cGT,3 times upper normal values;
bilirubin ,1.5 mg/dl
adequate bone marrow function (no gross abnormalities in thrombocytes
or leukocytes)
patient must be compliant
patient provided written informed consent
previous treatment with Abciximab (RheoproH)
thrombolytic therapy within previous 2 weeks except acute rTPA treatment for stroke
participation in another trial
global aphasia
any type of immediately necessary intervention, e.g. carotid endarterectomy
ulcerating plaque of carotid artery or pseudoocclusion
signs and symptoms of acute cerebral vasculitis
dissection of brain arteries relevant for acute symptomatology
previous disabling stroke events (ischemic or hemorrhagic stroke)
systemic malignancy
hematological system disorder (e.g. myeloproliferative disorder)
thrombocyte function disorders
metabolic syndrome with inadequate treatment parameters, e.g. excessive
hypertension, hyperlipemia, hyperglycemia
known deficit in hemostasis
serious coronary heart disease
sickle cell anemia
allergy against G-CSF (Neupogen H)
pregnancy
heavy smoker, daily use $20 cigarettes
immunosuppressive medication (e.g. glucocorticoids)
any other serious disease, for example: severe psychiatric disorder (major depression,
schizophrenic psychosis, addiction), severe cardiac disorder with hemodynamic
relevance), positive HIV serology
doi:10.1371/journal.pone.0023099.t001
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cerebral artery (ACA) territory in 1 patient (No. 13), and within
the vertebrobasilar territory in 2 patients (Patients 4 and 8). The
latter were regarded as minor protocol violations and not
excluded. In accordance with the study protocol, the dose of the
study drug was reduced from 2.5 mg to 1.25 mg in three patients in
whom the leukocyte count was .20,000/ml. After inclusion of 8
patients with high leukocyte counts but no adverse events, the
protocol was amended to a G-CSF dose reduction whenever the
leukocyte count exceeded 50,000/ml. None of the subsequent
patients met this criterion. In an additional patient the dose was
reduced from 10 mg to 5 mg because of another protocol violation.
Primary endpoint safety
A total of 4 patients (20%) experienced adverse events resulting
in termination of study drug treatment (Table 3). The remaining
16 patients (10 males/6 females) were determined to be the
evaluable population and were included in the final analysis for
study endpoints. Moderate thrombocytopenia without clinical
symptoms (platelet count ,150,000/ml) occurred in two patients.
A single patient was included with a baseline platelet count of
131,000/ml (a minor violation), but had an unremarkable follow-
up. Vital parameters—heart rate, blood pressure, and tempera-
ture—in all patients remained within normal limits. None of the
patients complained of pain. During G-CSF treatment and the
follow-up period none of the remaining patients experienced a
neurological deterioration, as assessed using the NIHSS, BI, and
mRS. All outcome scales indicated a good outcome at all time
points, as demonstrated in Figure 1A for the mRS and Figure 1B
for the NIHSS. All laboratory endpoints, including platelet and
erythrocyte counts, coagulation, and liver and renal parameters,
remained stable throughout the 90-day observation period. No
increase in infarct volumes was seen on serial MRIs between
48 hrs and 7 days, and no adverse findings were seen up to Day
90. In one patient, baseline MRI showed a middle cerebral artery
infarction in FLAIR and DWI images, but MRI on Day 90 did not
reveal any remaining lesion in FLAIR, T1-weighted, or T2-
weighted images.
CD34+ stem cell/progenitor mobilization
The number of CD34+ cells measured on Days 0, 1, 7, 28, and
90 increased from a median of 1653 cells/ml at baseline to a
median of 10,022 cells/ml on Day 7. No correlation was found
between the G-CSF dose and the mean CD34+ cell count; Fig. 2).
Total leukocyte counts (figure S2) also reflected successful
mobilization without an increase in inflammatory parameters
such as CRP (figure S1).
Voxel-guided morphometry
In almost all patients a slight volume increase within the
ischemic area was observed within the initial time frame (Day 1 to
Day 7); this was attributed to post-infarct edema. In most patients
atrophic changes in the gray matter of the affected side between
Table 2. Baseline characteristics of intention-to-treat population.
Patient No. Sex Age, yr Location Lysis MRS Stroke risk factors
ACA MCA VBT Yes no Pre-stroke Smoking Hypertension Diabetes Lipids
G-CSF Dose 2.5 mg/kg (BW)
1 M 59 + + 0 2 + 2 2
2 M 57 + + 0 2 2 2 2
3 M 56 + + 0 2 2 2 2
4 M 57 + + 0 + + + 2
5 F 55 + + 0 2 2 2 2
6 F 54 + + 0 2 + 2 2
7 F 61 + + 0 2 + 2 2
8 M 65 + + 0 + 2 2 2
G-CSF Dose 5 mg/kg (BW)
9 F 32 + + 0 2 2 2 2
10 M 54 + + 0 + + + +
11 M 64 + + 0 2 + 2 2
12 F 46 + + 0 2 2 2 2
13 F 55 + + 0 + + 2 +
14 M 52 + + 0 2 + 2 2
G-CSF Dose 10 mg/kg (BW)
15 M 53 + + 0 + 2 2 +
16 M 59 + + 0 2 + 2 2
17 M 64 + + 0 2 + 2 2
18 M 62 + + 0 2 + 2 2
19 M 64 + + 0 2 + 2 2
20 F 35 + + 0 2 + 2 2
Note: M=male; F = female; BW=Body weight ; ACA=anterior cerebral artery, MCA=middle cerebral artery, VBT=vertebrobasilar territory;
MRS=modified Rankin scale.
doi:10.1371/journal.pone.0023099.t002
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Table 3. Serious adverse events with time of onset, duration and outcome; ICP = intracranial pressure; ESR = erythrocyte
sedimentation rate.
SAE Term Patient No. Date of onset
Number of
G-CSF doses
received
Duration
(days) Relationship
Symptoms/AEs
associated with SAE
Patient
follow-up
Intracranial hemorrhage 3 hrs
after first s.c. injection of 5
mg/kg G-CSF, 12 hrs after
ischemia; patient was treated
with iv heparin with ptt 44 sec
Study medication withdrawn.
11 11 Jan 2004 1 17 Unlikely Nausea, vomiting, and
hemiplegia
Repeated
hemorrhages
without definite
diagnosis of
coagulation
abnormality or
thrombocyte
dysfunction
Increasing edema in the area
of infarction with rise of
intracranial pressure about 20
hrs after fourth s. c. injection
of 10 mg/kg G-CSF, about
110–120 hrs after ischemia
16 07 Jul 2005 4 10 Unlikely First nausea, vomiting
and increasing hemi-
paresis. Intubation and
application of ICP
sensor on 07/07/2005.
Pneumonia with
increase of CRP under
ventilation.
Stabilization
under anti-
edematous and
antibiotic therapy.
Extubation after
five days.
Pectanginous symptomatology
about 12 hrs after second s.c.
injection of 5 mg/kg G-CSF,
about 48 hrs after ischemia;
study medication withdrawn
17 08 Nov 2006 2 1 Unlikely No Controls of
cardiac enzymes
and ECG revealed
no pathology.
Suspected endocarditis.
Strongly accelerated ESR 10
hrs after first s.c. injection of
5 mg/kg G-CSF, about 21 hrs
after ischemia Echocardiography
showed moderate mitral
regurgitation with thickening
of leaflets; these results raised
suspicion of Libman-Sacks
endocarditis. Study medication
withdrawn.
20 04 Sep 2008 1 1 Unlikely Fatigue Controls of ESR
the next days
showed
normalized
values. Further
diagnostics
revealed no
autoimmune
disease
doi:10.1371/journal.pone.0023099.t003
Figure 1. Scores over time. MRS (Modified Rankin Scale) scores over time as median with minimum and maximum in three different dosage
groups (A). NIHSS (National Institutes of Health Stroke Scale) scores over time as median with minimum and maximum in three different dosage
groups (B).
doi:10.1371/journal.pone.0023099.g001
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Days 1 and 90 exceeded what we expected based on our analysis
of the T1-weighted images. Interestingly, in 2 patients (Patients 12
and 13) volume changes indicated some localized increases within
infarcted and atrophied areas. These patients underwent long-
term follow-up, which revealed persistent increases in the localized
volumes within ischemic areas. Individual anatomical MR images
obtained in the same patient were superimposed on previous
images to demonstrate the anatomical areas involved in this
structural change. After segmentation and linear alignment, the
slices were carefully arranged so that they could be compared
precisely on a voxel-by-voxel basis. This is shown in 2D in this
paper, but full 3D images were also prepared for the whole brain
volume, thus avoiding any interactive definition of regions of
interest (see Figure 3 a and b).
Volume change was quantified (see LUT below the sagittal
slices) locally. The LUT presents local volume changes in
percentages (20.2 = 20% volume decrease, 0.2 = 20% volume
increase). Green and blue regions represent volume reductions,
whereas yellow and red regions represent volume increases. In
Patient 12 after 3 months a small spot of volume augmentation
could be observed within the infarct area. After 5 years volume
increases could be detected in the patient’s frontal and parietal
areas as well as in a spottled distribution (arrow) within the
infarcted area ipsilaterally and in temporoparietal areas in the
contralateral hemisphere (Figure 3). In Patient 13, who suffered an
anterior cerebral artery infarction in the left hemisphere that also
involved the corpus callosum, volume augmentation within the
ischemic area—probably due to edema development—could be
observed after 5 days. After 3 months, a loss of volume could be
observed within the ischemic area accompanied by an increase in
the volume of the lateral ventricle. An area of volume increase
within the ischemic zone was seen. After 5 years, the frontal
volume loss spread beyond the infarcted area and included
adjacent white matter ipsi- and contralaterally. A slight volume
decrease was also observed in the posterior white matter and in
cortical areas in both hemispheres. The small area of volume
Figure 2. Absolute CD34+ cell count/ml over time as median
with minimum and maximum over time in the three different
dosage groups.
doi:10.1371/journal.pone.0023099.g002
Figure 3. VGM volume fields in Patients 12 (left) and 13 (right). Left: The first MRI, obtained within 48 hours after stroke onset, is compared to
MRIs obtained 4 days (A), 3 months (B), and 5 years (C) later. After 5 years, volume increases can be detected in a spotlike distribution (arrow) within
the infarcted area. Right: Volume fields are shown from MRIs obtained 5 days (A), 3 months (B), and 5 years after the first MRI had been obtained
immediately after stroke onset. A small area of volume increase (arrow) within the original ischemic zone, first seen after 3 months, still persists.
doi:10.1371/journal.pone.0023099.g003
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increase (arrow) within the original ischemic zone still persisted
(Figure 3).
Neurocognitive findings
Data in 8 of 16 patients (mean age 56.367.1 years) could be
analyzed for follow-up between Days 7 and 90. In the initial
assessment of the group the mean scores in working memory (digit
span backward, mean z=21), attention (Trail Making Test B,
mean z=21.3), and visual perception (Rey Complex Figure
Copy, mean z=21.5) were significantly lower than normative
data. In the second assessment on Day 90, only visual perception
had a mean score lower than 1 standard deviation (Rey Complex
Figure Copy mean z=21.5). Attention and working memory
were no longer impaired for the entire group. In the nonpara-
metric comparisons there was a significant improvement in verbal
(Wechsler Logical Memory II; Mt7=20.4, Mt90= 0.3, p,0.05)
and nonverbal (Rey Complex Figure Delay, Mt7=20.4,
Mt90= 0.3, p,0.05) long-term memory, as well as in attention
(Trail Making Test B, Mt7=20.4, Mt90= 0.3, p,0.05). No
significant deterioration in neurocognitive functions was identified
in the nonparametric comparison of Day 90 with Day 7. Details
are shown in Table 4.
Discussion
This is the first phase I/IIa trial in which standard IV
thrombolysis and daily administration of subcutaneous G-CSF in
a dose-escalating schedule were begun within the first 12 hours of
acute ischemic stroke, thus combining recanalization strategies
with a potentially regenerative treatment approach. Overall, the
study results confirm the safety and feasibility of administering
subcutaneous G-CSF during the acute stage of ischemic stroke. A
clear dose-response relationship between G-CSF administration
and CD34+ stem cell mobilization could not be established in this
rather small cohort. Median mobilization levels of up to 106103
cells/ml and peak levels of up to 296103 cells/ml were achieved.
Adverse events occurred in 4 patients, but they were regarded as
unrelated to the G-CSF treatment. Good clinical outcome
parameters and neurocognitive functions indicated safety and
good tolerance, as well as no functional impairment. The VGM
data revealed substantial atrophy around the infarcted territory; in
two cases additive localized gray matter within the infarct lesions
was seen.
In a recent study Scha¨bitz et al. assessed high intravenous doses
of G-CSF in patients with acute stroke [32]. Major differences
between that study and ours include the mode of drug
administration (intravenous vs. subcutaneous), length of drug
therapy (3 days vs. 5 days), and the fact that in our study tPA
therapy was allowed. Given our choice of subcutaneous rather
than intravenous administration, the systemic dose of G-CSF in
our trial was probably lower but perhaps induced longer-term
mobilization of hematopoietic stem cells.
Mobilization of CD34+ cells and safety
Augmented levels of G-CSF have been observed in a variety of
instances such as physical exercise [33,34], septic exposure to
various lipopolysaccharides [35], and exposure to lipoteichoic acid
[36], as well as in different types of ischemia [37–38]. G-CSF
transcripts are induced 65-fold at 16 hrs in experimental middle
cerebral artery occlusion [39]: it was concluded that G-CSF
induction in the brain may be part of an intrinsic stress response
aimed at neuroprotection. Since acute stroke is accompanied by
phases of breakdown of the blood-brain barrier, G-CSF could pass
into the systemic circulation and mobilize hematopoietic cells. The
Table 4. Neuropsychological assessment.
Differences between Day 7 and Day 90 in standard deviations
Patient No. 2 3 8 10 12 13 18 19
Mean
difference
statistical
significance
Long-term memory
Wechsler Logical Memory II 0.7 1.4 20.3 0.8 2 1.2 0.3 0 0.8 p,0.05
Wechsler Logical Memory I 0.8 1 20.5 1.4 1.5 1.5 0.8 20.1 0.6 not significant
Rey Complex figure Delay 0.5 1.5 0.8 20.5 2.2 0.9 0.5 20.1 0.7 p,0.05
Working memory
Digit span backward 0 0.8 0 0.7 0.7 0 0 0 0.4 not significant
Digit span forward 0 1.8 20.9 20.9 1.7 1.7 0 0.9 0.3 not significant
Block span 2 0 0 1 1 2 0 22.9 0 not significant
Attention
Trail making Test B 1 0.8 0 1.6 1.7 1.5 20.2 0 0.8 p,0.05
Ruff 2&7 0.2 0.4 0.4 0.4 0.2 n.a. 1.1 20.7 0.5 not significant
Lexical Fluency 0.8 20.1 0 1 1 0.8 0.2 20.5 0.4 not significant
Semantic fluency 0.4 2.2 1.8 20.7 0.3 0.4 0.1 20.6 0.6 not significant
Visual perception
Rey Complex Figure Copy 1.4 0.3 0 0.5 0.3 1.4 0.8 20.3 0.2 not significant
Trail Making Test A 20.4 0.7 0.3 0 0.9 20.4 1.3 0.4 0.4 not significant
Full scale IQ 20.8 0.2 0.4 1.6 0.8 0.3 0.5 20.5 0.3 not significant
Negative values used to describe a loss from Day 7 to Day 90; positive values to describe an improvement. A difference in z-scores under or above z =61 is bigger than
one standard deviation.
n.a. = not administered. Significance computed using the Wilcoxon test for repeated measures.
doi:10.1371/journal.pone.0023099.t004
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hypothesis of an invasion of these cells into the injured tissue and a
contribution to the initiation of cerebral repair seems tempting.
Indeed, mobilized G-CSF peripheral progenitor cells administered
intravenously have led to functional recovery in a rodent stroke
model [40]. Intravenous injection of CD34+ cells 48 hrs after
experimental brain ischemia reduced lesion size, enhanced
angiogenesis, and neurogenesis, and improved functional out-
come. It must be noted that angiogenesis and recanalization
provide a favorable environment for neuronal regeneration: when
CD 34+ cell-induced angiogenesis was blocked, neurogenesis was
reduced [41–42]; this finding underlines the probable importance
of CD34+ cell lesion access by recanalization therapy and the
potential relevance of the stem cell niche. In CD34+-transplanted
mice hematopoietic cells have been shown to differentiate into
microglial and perivascular cells after middle cerebral artery
occlusion; under these conditions a few cells were detected by
positive staining of the neuronal marker NeuN [43]. On the other
hand, neuronal and oligodendroglial gene products were detected
in CD34+ cells derived from murine bone marrow, with their
expression regulated in the brain [44].
In human adults CD34+ cells may differentiate into both
hematopoietic stem cells and endothelial progenitor cells [45,46].
Increasing evidence shows that circulating CD34+ cells contribute
to angiogenesis after brain infarction [47]. Therefore it seemed
reasonable to mobilize CD34+ cells in cases of acute cerebral
infarction to foster potential repair processes—neuroprotective or
even neuroregenerative. Translation of preclinical stroke research,
especially that done in rodents, is a tall order, and recent data
suggest multiple mechanisms of stem cell therapy for ischemic
stroke [48,49]. Dirk Hermann and his group recently suggested
multiple bystander effects of transplanted neuronal precursor cells,
such as reduction of inflammation, glial scar formation, and
neuronal apoptotic death contributing to functional recovery in
mice [50]. However, we cannot exclude true neuronal differen-
tiation following bone-marrow stem-cell mobilization, and the
complex mechanism in the injured brain that drives stem cells into
the neuronal or astrocytic lineage is not completely understood
[51]. Yet, the fate and function of hematopoietic or neuronal stem
cells in the much more complex human brain will be a new
challenge in stroke research and may be enhanced by techniques
such as VGM and fMRI.
We found that subcutaneous administration of G-CSF was
effective in mobilizing CD34+ stem cells into the peripheral blood
in patients with acute stroke. Rather high CD34+ cell counts were
obtained in the peripheral circulation, indicating enough cells for
potential treatment effects. CD34+ cell mobilization varied within
and among the different dosage groups; we were unable to
establish a clear-cut dose-response relation, probably due to a high
individual variation within small patient cohorts.
Our results in part contrast with those of the study by Sprigg
and coworkers. In their randomized, controlled trial they assessed
the safety of G-CSF administered for 5 days between Days 7 and
30 after stroke and the effect on circulating CD34+ stem cells.
Those authors detected an increase in CD34+ cells in a dose-
dependent manner [27]. The investigators started treatment at
the earliest time, 7 days after symptom onset, in order not to
interfere with leukocytosis seen during acute stroke: G-CSF-
induced leukocytosis might increase the risk of leukocyte plugging
of the microvasculature [52]. Our data indicate that high
leukocyte counts in the initial phase do not seem to be associated
with microembolism or sludging, as confirmed by findings of
another randomized trial [26]. Specifically, new lesions on T2-
weighted MR images were excluded, indicating an absence of
obvious or silent additional embolic events. For leukocyte counts
see figure S2. In a recent trial we were able to show that stroke
leads to spontaneous increases in serum G-CSF and CD34+ cells
[10]. Additional G-CSF may lead to an interference of
spontaneous and induced G-CSF levels, and add to the effects
of individual quality and quantity of mobilization at different time
points. This may confound dose-response relationships in G-CSF
trials. Moreover, our study is the first to indicate that the co-
administration of G-CSF and rtPA is safe in patients with acute
stroke. Five of our 20 patients received intravenous rtPA and
none experienced intracerebral hemorrhage or other events
relevant to safety issues. Clearly safety is an issue that needs
further investigation.
Adverse events occurred in four of our remaining patients. A
relationship between adverse effects and the study drug was
unlikely in all cases. In one patient intracranial hemorrhage
occurred 3 hrs after study drug administration and 12 hours
after stroke onset. Laboratory results showed no thrombocyto-
penia or thrombocyte dysfunction but the patient was treated
with IV heparin because cardioembolic stroke was suspected. A
relationship between intracranial hemorrhage and G-CSF
treatment seemed unlikely, but the use of anticoagulants in
addition to G-CSF treatment should be carefully investigated in
future trials.
Respiratory infections are a major contributor to morbidity
following ischemic stroke; however, in our study treatment was not
associated with an additional risk of infection. For CRP counts see
figure S1. One patient developed pneumonia 1 day after cessation
of G-CSF administration due to aspiration but a causal effect of G-
CSF is very unlikely. In addition, a double-blind, placebo-
controlled study showed safe but not efficacious administration
of G-CSF in patients with pneumonia and severe sepsis [53]. In
our study both suspected cardiac side effects were regarded to be
completely unrelated (Table 3). Other systemic side effects,
specifically bone pain or headaches, were not observed.
Outcome parameters
Good functional outcomes were obtained in all of our patients.
MRI investigations in our study displayed the expected structural
changes after stroke. Interestingly, in one patient MRI obtained on
Day 90 showed no remaining lesion on FLAIR and T1-weighted
sequences. In addition we analyzed intra-individual brain volume
changes over time using VGM [30,54]. This is in line with a study
by Kraemer et al., who showed secondary brain atrophy after
stroke of the middle cerebral artery territory in 10 patients.
Interestingly, and in contrast to our study, those authors did not
detect any volume increase in either the acute or chronic state
[54]. In 2 patients we were able to delineate a small volume
increase in the infarct area (Figure 3). The interpretation of these
findings clearly requires further investigations.
Due to the study design (phase I/II dose-escalation) and the
small number of patients, additional subgroup analyses of
outcomes were not performed, These should be addressed in
further trials.
To our knowledge to date there is no information about the
effects of G-CSF on cognition in stroke patients. Gibson et al.
showed a beneficial effect of a single dose of G-CSF on cognitive
deficits in transient focal ischemia in mice [22]. Our study is the
first to describe neuropsychological findings in G-CSF-treated
patients in acute stroke. The comparison of neurocognitive
performance on Days 7 and 90 showed significant improvements
in long-term memory and attention. There was no significant loss
of function, so treatment with G-CSF at least does not seem to
have adverse effects on neurocognitive function.
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Conclusion
The results of our study demonstrate a good safety profile for
daily G-CSF injections when begun within 12 hours of acute
stroke, even in combination with IV thrombolysis. Additional
analyses involving voxel-guided morphometry and a battery of
neuropsychological tests in some of our patients hint toward a
positive functional regenerative effect of G-CSF treatment.
Further studies should focus on the time window within which
G-CSF treatment should commence, the length of this treatment,
and on dose-response and structural effects.
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